Thakur M, Babu A, Khatik GL, Datusalia AK, Khatri R, Kumar A. Role of baricitinib in COVID-19 patients: A systematic review and meta-analysis. World J Meta-Anal 2023; 11(4): 125-133 [DOI: 10.13105/wjma.v11.i4.125]
Corresponding Author of This Article
Anoop Kumar, PhD, Assistant Professor, Department of Pharmacology and Clinical Research, Delhi Pharmaceutical Sciences and Research University, New Delhi 110017, Delhi, India. abitmesra@gmail.com
Research Domain of This Article
Pharmacology & Pharmacy
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Manisha Thakur, Ashok Kumar Datusalia, Department of Regulatory Toxicology, National Institute of Pharmaceutical Education and Research, Raebareli, Raebareli 226002, India
Akhil Babu, Gopal Lal Khatik, Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, Raebareli, Raebareli 226002, India
Ramchander Khatri, Department of Pharmacognosy, Delhi Pharmaceutical Sciences and Research University, New Delhi 110017, India
Anoop Kumar, Department of Pharmacology and Clinical Research, Delhi Pharmaceutical Sciences and Research University, New Delhi 110017, Delhi, India
Author contributions: Thakur M and Babu A contributed to searching and selection of studies, extraction of data; Khatik GL, Datusalia AK, and Khatri R contributed to cross verification of data; Khatik GL contributed to first draft of the manuscript; Datusalia AK and Khatri R contributed to revision; Kumar A contributed to design, analysis and final rthe evision of manuscript; All authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Anoop Kumar, PhD, Assistant Professor, Department of Pharmacology and Clinical Research, Delhi Pharmaceutical Sciences and Research University, New Delhi 110017, Delhi, India. abitmesra@gmail.com
Received: October 31, 2022 Peer-review started: October 31, 2022 First decision: January 17, 2023 Revised: January 27, 2023 Accepted: March 29, 2023 Article in press: March 29, 2023 Published online: April 18, 2023 Processing time: 179 Days and 7.3 Hours
Abstract
BACKGROUND
Recent studies have indicated the use of baricitinib in coronavirus disease 2019 (COVID-19) patients. However, the use of baricitinib in COVID-19 patients is unclear so far.
AIM
To determine the precise role of baricitinib in the mortality of COVID-19 patients.
METHODS
The relevant studies were searched in PubMed, Google scholar, and Clinical trials registries till July 13, 2021 and sorted out based on inclusion and exclusion criteria. The quality of studies was assessed using Newcastle-Ottawa Scale. A random-effect model was used, and the pooled estimate was calculated as the odds ratio with a 95% confidence interval using Rev Man 5.
RESULTS
A total of 11 studies (4 observational and 7 clinical trials) were found relevant for analysis. The overall estimate measure in terms of odds ratio for observational studies was 0.42 [0.11, 1.67], whereas for clinical trials it was 0.37 [0.09, 1.46], indicating a non-significant reduction in COVID-19 patient deaths in the baricitinib group versus the non-baricitinib group.
CONCLUSION
More studies are required to confirm the role of baricitinib in the deaths of COVID-19 patients.
Core Tip: Emerging reports have indicated the use of baricitinib in hospitalized coronavirus disease 2019 (COVID-19) patients. However, the use of baricitinib in COVID-19 patients is unclear so far. Current study aimed to find out the exact association of baricitinib in the mortality of COVID-19 patients.
